Slideshow: 2023 Vaccine Approvals
Vaccine approvals included two immunizations for RSV and a new pentavalent meningococcal shot.
This year was a year of firsts in the immunization space1: In addition to the first vaccines to protect against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in older adults and the first RSV vaccine for use in pregnant people to protect newborns, 2023 saw the first vaccine for adults at increased risk of exposure to chikungunya virus made its debut. Additional approvals included a new meningococcal vaccine that simplifies a complex immunization schedule.
References
1. 2023 biological license application approvals. FDA. Reviewed November 27, 2023. Accessed November 28, 2023. https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2023-biological-license-application-approvals
2. FDA approves first respiratory syncytial virus (RSV) vaccine. News release. FDA. May 3, 2023. Accessed November 28, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine
3. US FDA approves Abrysvo, Pfizer’s vaccine for the prevention of respiratory syncytial virus (RSV) in older adults. News release. Pfizer. May 31, 2023. Accessed November 28, 2023. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention
4. Emergent BioSolutions receives US FDA approval of Cyfendus (anthrax vaccine adsorbed, adjuvanted), previously known as AV7909, a two-dose anthrax vaccine for post-exposure prophylaxis use. News release. Emergent BioSolutions. July 20, 2023. Accessed November 28, 2023. https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-receives-us-fda-approval-cyfendustm
5. US FDA approves Abrysvo, Pfiver’s vaccine for the prevention of respiratory syncytial virus (RSV) in infants through active immunization of pregnant individuals 32-26 weeks of gestational age. News release. Pfizer. August 21, 2023. Accessed November 28, 2023. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention-0
6. FDA approves Penbraya, the first and only vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents. News release. Pfizer. October 20, 2023. Accessed November 28, 2023. https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-penbrayatm-first-and-only-vaccine-prevention
7. Pfizer’s Penbraya receives recommendation for prevention of meningococcal disease in adolescents and young adults from Advisory Committee on Immunization Practices. News release. Pfizer. October 25, 2023. Accessed November 28, 2023. https://www.pfizer.com/news/announcements/pfizers-penbrayatm-receives-recommendation-prevention-meningococcal-disease
8. Valneva announces US FDA approval of world’s first chikungunya vaccine, Ixchiq. News release. Valneva. November 10, 2023. Accessed November 28, 2023. https://valneva.com/wp-content/uploads/2023/11/2023_11_10_BLA_Approval_PR_EN_Final_.pdf
9. FDA approves first vaccine to prevent disease caused by chikungunya virus. News release. FDA. November 9, 2023. Accessed November 28, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-prevent-disease-caused-chikungunya-virus
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
